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Abstract
This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Du¨sseldorf, Germany,
from 9 to 12 September 2009. Five challenges have been identified: (1) safeguarding the principles of medical ethics;
(2) optimizing the risk/benefit ratio; (3) bridging the gap between multiple sclerosis and experimental autoimmune
encephalitis; (4) promoting neuroprotection and repair; and (5) tailoring multiple sclerosis therapy to the individual
patient. Each of these challenges will be discussed and placed in the context of current research into the pathogenesis
and treatment of multiple sclerosis.
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Introduction: history of ECTRIMS
According to Otto Hommes and Richard Gonsette, pio-
neers and early witnesses of the European Committee for
Treatment and Research in Multiple Sclerosis
(ECTRIMS), one of the first meetings in the series was
held in the Dutch city of Nijmegen in 1982. The proceed-
ings of that meeting, entitled ‘Immunotherapies in
Multiple Sclerosis’, were edited by Hommes, Mertin
and Tourtellotte (Figure 1). The first meeting that offi-
cially carried the name ECTRIMS in its title was held in
Lyon, France, in 1987. Its proceedings were entitled
‘Trends in European Multiple Sclerosis Research, edited
by Confavreux, Aimard and Devic (Figure 1).
It is remarkable from today’s perspective that these
early meetings were attended by no more than 50 to 80
people. By comparison, the ECTRIMS meetings held in
Madrid in 2006, and in Prague in 2007, were attended by
between 4000 and 5000 participants (Figure 2) – almost
100 times as many as in the early days! This impressive
growth reflects the growth of multiple sclerosis (MS) ther-
apeutics, which accelerated after the first disease-
modifying agent, interferon beta 1-b, had been approved
in 1993. MS has since become an important market,
promising substantial profits for pharmaceutical compa-
nies. Financial support by industry has allowed the
number of participants attendingMSmeetings to expand.
Future challenges in multiple sclerosis
For the ECTRIMS lecture presented at the 25th
ECTRIMS meeting in Du¨sseldorf in September 2009,
I selected five challenges, which are all related either to
MS therapeutics or MS pathogenesis (Figure 3). There
are so many challenges ahead of us, that identifying
‘future challenges in MS’ presents a challenge in itself.
Readers may come up with additional or altogether
different challenges.
Challenge #1: safeguarding the principles of medical
ethics
The sales of MS products have steadily increased
during the past decade. Currently they amount to
about 8 billion US dollars, equally divided between
the USA and Europe (Figure 4). This is in a similar
range as some of the blockbuster drugs used for treat-
ing more prevalent diseases, such as cardiovascular
disorders. Compared with the more prevalent
diseases, however, the number of patients with MS is
relatively small, as is the number of neurologists spe-
cializing in MS (Figure 5). Therefore, in MS a single
prescription is often worth thousands of dollars
or Euros. Against this background it is sometimes
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challenging to safeguard and maintain the principles
of medical ethics. Several areas of concern can be
identified (Box 1). For example, it is becoming
more and more difficult to perform placebo-controlled
trials in MS, although this trial format has produced
invaluable information. Are placebo-controlled
trials still feasible? Are they ethical at a time when
more and more effective treatments are available?
These are difficult questions which were recently
addressed in an excellent review article by Polman
et al.1 A related ethical issue is the increasing tendency
to move therapeutic trials to less affluent countries.1
Further, there is still a relative lack of head-to-head
studies, mostly because industry sponsors are reluctant
to support trials that could produce unwelcome results.
Figure 1. Early ECTRIMS meetings held in Nijmegen,
Netherlands (1982), and in Lyon, France (1987). Figure 2. Rising number of ECTRIMS participants.
Figure 4. Growing sales ofmultiple sclerosis therapeutic products.
RoW: Rest of World, IMS: Intercontinental Marketing Services.
Figure 3. Five challenges related to MS therapeutics and pathogenesis.
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On the other hand, there is a notorious paucity
of investigator-driven studies, and a strong bias
against the publication of negative results. All these
problems have long been identified, but are far from
being solved.
Apart from such fundamental ethical issues of drug
development, there are other problems that should be
easier to overcome. These include the bad habit of
‘ghost writing’ of review articles or even original papers
by sponsor-paid, anonymous authors; flimsy ‘surveillance
studies’ (phase IV studies) which often have the purpose
only of keeping patients on a particular drug, or of pla-
cing themon a newdrug; ‘prescription tracking’, allowing
sales representatives to monitor the prescription
behaviour of individual doctors; and all sorts of
marketing activities disguised as education. Despite
these concerns, there is no question that drug develop-
ment in MS depends on strong input and support
from the pharmaceutical industry. Both the medical
profession and industry equally share the
responsibility for safeguarding the principles of
medical ethics.
Challenge #2: optimizing the risk/benefit ratio
The first generation of ‘disease-modifying drugs’
(DMD), interferon beta and glatiramer acetate, com-
bines moderate efficacy with an excellent safety record.
A new generation of therapies, including new monoclo-
nal antibodies, such as alemtuzumab and daclizumab,
as well as oral agents such as fingolimod, cladribine,
fumaric acid, teriflunomide, and laquinimod, seems to
be somewhat more efficacious than the existing DMDs,
but brings along new risks.2 Ideally, drug development
should achieve evermore increasing efficacy, while
maintaining a benign risk profile (bent curve in
Figure 6). Whether this lofty goal can be achieved
remains to be seen. In the meantime, with the growing
complexity of MS therapy, there is a growing need for
common-sense guidelines which help to translate the
results of therapeutic trials into treatment decisions
for individual patients. Such consensus guidelines are
regularly provided by professional societies such as the
American Academy of Neurology, and national and
international panels of independent experts such as
Figure 5. (Fictive) relationship between the number of
patients (top), physicians (middle) and therapeutic market
(bottom). MS (left) is compared with other, more prevalent
diseases (right).
Figure 6. Optimizing the risk to benefit ratio of therapeutic
agents used for multiple sclerosis. Realistically, increasing efficacy
is accompanied by increasing risk. Ideally, risk should remain low
despite increasing efficacy.
Box 1. Some areas of ethical concern
 Placebo-controlled
trials: still feasible/ethical?
 Tendency to move trials to
less affluent countries
 Relative lack of
head-to-head-studies
 Paucity of
investigator-driven studies
 Bias against publication
of negative results
 Marketing disguised
as education
 Surveillance studies  Prescription-tracking  Ghost writing
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the MS therapy consensus group MSTKG, which
started in the German-speaking countries, but has
since developed into a concerted European effort.3
Challenge #3: bridging the gap between multiple
sclerosis and experimental autoimmune
encephalomyelitis
Figure 7 shows a typical schematic representation of
experimental autoimmune encephalomyelitis (EAE)
and MS pathogenesis (adopted from Hohlfeld,4 with
permission). According to this widely held ‘T-cell cen-
tric’ view, potentially autoaggressive T cells exist even
in the normal immune system. After initial activation
(which occurs outside the central nervous system
(CNS)), the autoreactive T cells acquire the capacity
to traverse the blood–brain barrier and migrate into
the CNS where they become locally re-activated.
After reactivation, the T cells orchestrate a complex
series of interactions culminating in the destruction of
both myelin and axons. It is important to remember
that our current thinking about the pathogenesis of
MS is built to a large extent on results obtained in
EAE. However, there is still a wide gap between
research in human MS and its animal models.5,6
Bridging this gap remains a major challenge.
Fortunately, progress in experimental technology is
helping to achieve this. New techniques include cellular
and molecular in vivo imaging; genetically engineered
animal models; transcriptomics and proteomics
approaches; and single-cell ‘resurrection’ from archival
human tissues.
Cellular and molecular in vivo imaging: In what is
now considered a classical experiment, Ben-Nun et al.
demonstrated that purified myelin basic protein
(MBP)-specific CD4+ T-cells are sufficient to induce
EAE.7 They isolated MBP-specific T-cells from the
lymph nodes of MBP-immunized rats, and cultured
the cells in vitro in the presence of MBP. In this way,
they could purify and expand long-term ‘lines’ of
MBP-specific T cells. The T line cells were then injected
into healthy recipients of the same rat strain from
which the T cells had been originally isolated.7 After
a lag phase of 4 to 5 days, the recipients of the purified
MBP-specific T cells developed EAE. This experiment
has become one of the pillars of EAE research, and
especially of the ‘T-cell centric’ view of MS pathogen-
esis (Figure 8).
Subsequently, the T-cell transfer system could be
further refined, allowing spectacular insights into cru-
cial steps of EAE pathogenesis. For example, Flu¨gel
and Wekerle developed a technique for permanently
labelling MBP-specific T cells in vitro with a fluorescent
dye, green fluorescent protein (GFP).8 For this pur-
pose, the T cells are transduced in vitro with a
GFP-carrying viral vector. As a consequence, they
become fluorescent. The GFP-labelled T cells are then
injected into a healthy recipient rat, according to the
classical T cell transfer approach (Figure 8). The spinal
Figure 7. Schematic view of multiple sclerosis pathogenesis. See text for details. From Hohlfeld,4 with permission.
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cord of the recipient animals is surgically exposed, so
that the in vivo behaviour of the transferred
GFP-labelled autoreactive T cells can be directly
observed under a 2-photon microscope. This allows,
for example, real-time imaging of the transmigration
of autoreactive T cells from the blood into the sur-
rounding tissue. By imaging T-cell traffic in and
around meningeal spinal blood vessels, Bartholoma¨us
et al. recently identified several new features of this cru-
cial process.9
The first striking observation was that, contrary to
current dogma, T cells do not just ‘roll’ with the blood
stream along the endothelium, but rather they actively
crawl, oftentimes in a direction against the blood
stream (phase 1; Figure 9). Next, the crawling T cells
stop and squeeze through the vessel wall (diapedesis;
phase 2). Subsequently, the T cells crawl along the out-
side of the blood vessel (phase 3). During the course of
its extravascular crawling, the T cell encounters a peri-
vascular antigen-presenting cell, e.g. a dendritic cell. If
the antigen-specific receptor of the T cell recognizes ‘its’
antigen on the surface of the dendritic cell, the T cell is
re-activated, and thereby becomes ‘licensed’ to leave the
area of the vessel and penetrate into the surrounding
tissue (phase 4).
These observations help to dissect the crucial pro-
cess of T cell transmigration with new precision.
Obviously the findings are also relevant for therapy,
as is exemplified by the already approved monoclonal
antibody against a4b1 integrin called natalizumab. The
effect of anti-a4b1 integrin antibody on T-cell crawling
has been nicely captured in a movie.10 After injection of
the antibody, intravascular crawling of T cells is
completely abolished. The movie shows how the
blood vessels are literally flushed free of adhering
T cells.
Genetically engineered animal models: Modern EAE
research relies on genetically engineered animals.
State-of-the-art methods make it possible to switch on
or switch off specific genes in specific tissues, enabling
investigators to perform extremely sophisticated experi-
ments. If, for example, a particular fluorescent dye is
inserted into certain cells of the nervous system, and
another, different, dye is used for labelling a certain
subtype of immune cells, in vivo imaging technology
can be applied elegantly to visualize the interaction
between the distinctly labelled cells.11
‘Spontaneous’ EAE models represent another
advance made possible with genetically engineered ani-
mals. Whereas classical EAE is induced by active
immunization with autoantigens such as MBP, or by
transfer of MBP-specific T-cells, in spontaneous EAE
the animals develop clinical symptoms without any
external manipulation. This is illustrated with a new
relapsing mouse model of spontaneous EAE, stun-
ningly mimicking the clinical course of human MS:
SJL/J mice carrying a T-cell receptor specific for
myelin oligodendrocyte glycoprotein (MOG) develop
relapsing EAE with spontaneous symptoms often alter-
nating between different CNS locations such as the cer-
ebellum, optic nerve and spinal cord.12 A movie
demonstrates the spontaneous relapsing-remitting
course of such a transgenic mouse.13 This model is an
excellent test system for novel immunotherapies.
Further, these animals are ideally suited for studying
the influence of environmental factors on the course
and development of disease.
Figure 8. Different types of experimental autoimmune
encephalomyelitis (EAE). EAE can be induced by active immuni-
zation with autoantigen (e.g. MBP, myelin basic protein; left), or
by transfer of purified, MBP-specific CD4+ T cells (T-cell transfer
EAE, right). Green animals ¼ healthy; red animals ¼ EAE.
Figure 9. Four phases of T-cell migration across the blood–brain
barrier (BBB). See text for details.
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Genetically engineered mice are not only essential
tools for unravelling the molecular details of EAE
pathogenesis, but also for investigating fundamental
principles of immunology in general. One of the most
prominent advances in this regard is the discovery of
several new types of T cells. According to the tradi-
tional scheme, CD4+ T cells come in two varieties,
called TH1 and TH2. More recently, other types of
T cells have entered the limelight. So-called regulatory
T cells (Treg) suppress and control the naturally existing
autoreactive immune cells. Another new subtype of
T cell, called TH17 cells, plays a significant role as
pathogenic effector T-cells in EAE, and possibly MS.
There is a complex developmental relationship between
the Treg and the TH17 cells, and it is difficult to ascribe
a purely beneficial (or detrimental) function to any one
subset.14
With the discovery of Th17 cells and Treg, the com-
plexity of the CD4 T-cell population has considerably
extended (Figure 10). Nevertheless, the new scheme is,
of course, still a gross oversimplification. Many addi-
tional types of immune cells, including CD8+ T cells, B
cells, macrophages, different types of dendritic cells,
natural killer (NK) cells, NKT cells, and many others,
likely contribute to the immunopathogenesis of EAE
and MS.
Transcriptomics and proteomics techniques:
‘Unbiased’ (‘omics’) approaches have identified many
novel molecular targets and pathways in many areas of
biology and medicine. MS is no exception: pioneered by
Steinman and colleagues, transcriptomic15 and proteo-
mic analyses16 of MS tissue have revealed important
insights into the pathogenesis of MS, leading to
identification of novel therapeutic targets, such as
osteopontin17 and angiotensin converting enzyme18.
The essence of this approach, which is geared to brid-
ging the gap between EAE and MS, is illustrated in
Figure 11. Starting with an unbiased ‘omics’ analysis
of MS tissue, candidate mRNA or protein molecules
are identified by comparing the expression profiles of
MS and control tissues. Next, the potential functional
role of the candidate molecules is tested in EAE models.
If the EAE experiments support the hypothesis, it
makes sense to further explore the newly identified mol-
ecule or mechanism in human MS.
Single-cell ‘resurrection’ from human tissue: Another
approach for bridging the gap between EAE and MS is
the ‘resurrection’ of particular immune cells from
autopsy or biopsy tissue of MS patients.19 Most immu-
nological investigations in human MS are done with
living immune cells isolated from the blood or cere-
brospinal fluid (CSF). One disadvantage is that these
cells are captured far away from the crime scene, the
MS lesion in the CNS. It is therefore only logical to try
to analyse immune cells directly in the CNS. One prob-
lem of this more direct approach is that CNS samples
from MS patients are scarce and, if they are available,
they are usually frozen or fixed, containing only
dead cells.
Each B cell or T cell carries one type of ‘clonotypic’,
antigen-specific surface receptor. Clonotypic refers to
the fact that the existing billions of different
antigen-specific receptors are distributed over billions
of different ‘clones’ of immune cells. Each receptor mol-
ecule is composed of a pair of two different chains,
called TCR alpha and beta in the case of T-cell
Figure 11. Combination of transcriptomics and proteomics
analyses of human multiple sclerosis tissue with functional
experiments in experimental autoimmune encephalomyelitis.
Figure 10. Growing complexity of CD4+ T cells. Th1: T helper
1 cells, Th2: T helper 2 cells, Th17: Interleukin-17-producing T
cells, Treg: regulatory T cells. Thumbs up ¼ protective cell type;
Thumbs down ¼ pathogenic cell type. See text.
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receptors (TCR). Using laser capture micro-dissection
to isolate individual tissue-infiltrating T cells
(Figure 12)20, and polymerase chain reaction (PCR)
to amplify the TCR transcripts contained in each
microdissected cell, it is possible to identify the com-
plete cDNA (and by inference, amino acid) sequence of
the paired alpha and beta chains in each dissected T
cell.21 This strategy involves sophisticated multiplex
PCR. Further, the PCR need to be miniaturized
down to the level of single cells. This is necessary
because PCR analysis of bigger pieces of tissue (con-
taining many different clones of T cells) would yield
myriad different TCR alpha and beta chains, making
it impossible to identify the correct pairings of chains.
In our laboratory this technology has now advanced
to the stage where several TCR alpha and beta chain
pairs could be identified from CNS tissue-infiltrating T
cells. Once the matching alpha/beta chain pairs have
been identified from individual tissue-infiltrating T
cells, the corresponding TCR proteins can be function-
ally expressed in a living (mouse) cell line which can be
co-transfected with appropriate additional humanmole-
cules and then be used to search for the target antigen(s)
using in vitro assays (Figure 13). In this way, it should
eventually be possible to track down the target antigens
recognized by the T cells in MS tissue. In parallel, it
might be possible to insert the human TCR identified
from human tissue into genetically engineered mice.
This would allow investigation of the potentially patho-
genic properties of such human TCR in vivo. In princi-
ple, humanized, TCR-transgenic mice can indeed be
constructed, as was elegantly shown by Fugger and
colleagues.22 They provided proof-of-principle that
such models can be most valuable for studying
antigen-specific human TCR in vivo.
Challenge #4: promoting neuroprotection and repair
The observation that irreversible neuronal and axonal
damage occur early during the course of MS has gained
great importance for MS therapeutics. However, pres-
ently only the inflammatory component of the patholog-
ical process can be effectively targetedwith existing drugs.
Although it is likely that immunomodulatory agents
reduce demyelination, and thus indirectly also axonal
loss, it is unclear whether the existing therapies have a
primary neuroprotective component. Inflammation is
usually considered detrimental in MS pathogenesis.
However, there is no doubt that inflammatory reactions
may be beneficial, as can be illustrated with the example
of wound healing. By analogy, CNS inflammation also
likely has a beneficial component.
Neuroprotective role of inflammation: On the one
hand, there is a close correlation between inflammation
and neurodegeneration.23–26 On the other hand, inflamma-
tion may contribute to protection and repair.27 The ‘net
effect’ of inflammation – destruction or protection – is
obviously determined by the relative weight of these pro-
cesses in any specific inflammatory condition or
situation.28 Some years ago, we observed that brain-
infiltrating inflammatory cells in MS and other inflamma-
tory CNS disorders produce abundant amounts of
brain-derived neurotrophic factor (BDNF)29 (Figure 14).
Figure 12. Laser-assisted microdissection of single T cells from
MS brain tissue. Green stain ¼ T-cell receptor variable region 5
(TCR V-beta 5); Red stain ¼ CD8 (marker for cytotoxic T cell).
The four numbered, dissected T cells are double-positive for
both markers (right panel). From Junker et al.20 with permission
of the publisher.
Figure 13. Resurrection of tissue-infiltrating T cells frommultiple
sclerosis brain (autopsy or biopsy). First, both chains of the antigen-
specific T cell receptor (TCR) of the dissected human T cell (green)
are identified as described in the text. Next, the TCR is expressed in
a living mouse cell line (brown). The TCR transfectants can then be
used for identification of the unknown target antigen.
Hohlfeld 9
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The cognate receptor for BDNF, TrkB, is expressed on
neurons and astrocytes in the direct vicinity of
brain-infiltrating immune cells.30 These observations led
us to speculate that inflammatory cells may ‘import’ neu-
rotrophic factors such as BDNF into the brain, and that
local secretion of BDNF by inflammatory cells can medi-
ate neuroprotective effects. Recent experiments by Linker
and Gold provide functional support for this concept
(personal communication). Conditional knock-out mice
lacking BDNF in macrophages or T cells show a more
progressive and severe course of chronic EAE. This is con-
sistent with the notion that BDNF imported by immune
cells has a beneficial role in the CNS milieu. It seems rea-
sonable to assume that it depends on the stage and type of
lesion whether the destructive or protective role of inflam-
mation prevails. This concept is relevant for all types of
immunosuppressive therapy.
Secondary axonal damage: At least part of the
axonal damage observed in MS is likely to be secondary
to demyelination (Figure 15). Several mechanisms
might account for secondary axonal damage. First,
axons might suffer collateral damage when myelin is
acutely attacked by immune cells.31 Second, chronic
demyelination might lead to a state of chronic meta-
bolic deficiency of axons.32 It appears that the increased
energy demand of impaired conduction along demyeli-
nated axons and reduced axonal ATP production
induce a chronic state of ‘virtual hypoxia. This leads
to disturbance of mitochondrial function, sodium influx
through voltage-gated Na+ channels and axonal
AMPA receptors, calcium release from intracellular
stores, overactivation of axonal glutamate receptors,
and activation of voltage-gated calcium channels.32
This cascade culminates in the activation of
calcium-dependent toxic pathways. The concept of vir-
tual hypoxia forms the basis for several therapeutic
neuroprotective strategies, some of which target
common pathways shared between inflammatory and
degenerative CNS diseases (Box 2).33
Figure 14. Immunohistological localization of brain-derived neurotrophic factor (left: BDNF stain; right: negative control) in
inflammatory cells surrounding a blood vessel in human brain. From Kerschensteiner et al.29  Kerschensteiner et al., 1999. Originally
published in J. Exp. Med. 189:865–870.
Figure 15. Axonal injury secondary to demyelination.
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Primary axonal damage: In addition to secondary
axonal damage, axons may also be the primary targets
of immune-mediated damage, in the absence of demye-
lination. In principle, such primary axonal damage
could be mediated by the so-called adaptive immune
system (that is, antigen-specific T cells or antibodies),
or by the innate (antigen-nonspecific) immune system
(Figure 16). Indeed, there is evidence to support both of
these possibilities. The recently discovered autoantibo-
dies against neurofascin may serve as an example of the
first possibility, damage inflicted by the adaptive
immune system.
Neurofascin exists in two isoforms, NF155 and
NF186. NF155 is expressed in the paranodal loops of
myelin, whereas NF186 is expressed on the nodal sur-
face of axons. Starting with a proteomics-based
approach, Mathey et al. detected neurofascin-specific
autoantibodies in serum samples of patients with
MS.34 The antibodies cross-reacted with both isoforms
of neurofascin. To evaluate whether these antibodies
are pathogenic in vivo, the investigators co-transferred
a neurofascin-specific monoclonal antibody together
with MOG-specific T-cells. In this co-transfer model,
the anti-neurofascin antibodies bound to the nodes of
Ranvier, resulting in local deposition of complement,
axonal injury and disease exacerbation (Figure 17).34
A recent example of the second mechanism of pri-
mary axonal injury – damage inflicted by the innate
immune system – is a newly discovered process of
axonal degeneration observed by in vivo imaging of
EAE lesions (Kerschensteiner and Misgeld, personal
communication). In the vicinity of infiltrating immune
cells axons undergo a series of changes, starting with
focal swellings and culminating in multi-focal fragmen-
tation. The changes appear to be mediated by macro-
phage-derived reactive oxygen species (Figure 18).
Importantly, there is an intermediate stage of axon
damage that is reversible, offering encouraging perspec-
tives for neuroprotective therapy.
Figure 18. Primary axonal damage mediated by diffusible toxic
mediators, e.g. reactive oxygen or nitrogen species produced by
macrophages in experimental autoimmune encephalomyelitis
lesions.
Figure 16. Primary axonal damage (occurring prior to demye-
lination), mediated by T cells or specific antibodies. CTL: cytotoxic
T cell.
Figure 17. Primary axonal injury mediated by antibodies
against neurofascin at the node of Ranvier.34
Box 2. Candidate neuroprotective therapies
 Na channel blockers  Glutamate receptor
antagonists
 Immunomodulators:
IFN-b, GLAT, Fingolimod,
Dimethyl fumarate?
 Reactive oxygen and
nitrogen scavengers
 Calpaine inhibitors  Cannabinoids
 Minocycline  Growth factors
 Cell therapy  Remyelination
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Challenge #5: ‘tailoring’ MS therapy to the individual
patient
With an increasing number of available therapies, the
‘one-size-fits-all’ treatment model becomes outdated.
Ideally, therapy should be tailored to the specific
demands of each individual patient. Obviously, we are
still far from the goal of ‘personalized medicine’.
Customized therapy will only become possible when
biomarkers become available allowing the reliable iden-
tification of therapeutically relevant subgroups of
patients. Therefore, ‘tailored therapy’ and ‘disease mar-
kers’ are really two sides of the same coin (Figure 19).
There are different types of biomarkers for different
aspects of disease (Box 3A, 3B) (reviewed by Bielekova
and Martin).35 Among the most impressive examples of
a successful immunological biomarker are the
anti-aquaporin-4 antibodies now serving as diagnostic
markers of neuromyelitis optica.36 Initially these anti-
bodies were identified as a diagnostic marker of a par-
ticular clinical syndrome that is now separable from
MS. Using a co-transfer model similar to that described
above for anti-neurofascin antibodies, several groups of
investigators have now shown that anti-aquaporin-4
antibodies are pathogenic in vivo when co-injected
with myelin-specific T cells.37–39 This observation
serves to illustrate an important more general point:
potentially pathogenic antibodies can reach the CNS
only after the blood–brain barrier has been breached.
This principle was established in the early 1980s with
anti-MOG antibodies. When anti-MOG antibodies are
injected into healthy animals, nothing happens. If, how-
ever, they are co-injected with MBP-specific T cells,
transfer-EAE is exacerbated.40,41 In this model, the
MBP-specific T cells breach the blood–brain barrier
and make it permeable to antibodies. A parallel
approach was used to demonstrate the pathogenic
potential of anti-neurofascin and anti-aquaporin-4
antibodies.34,37–39
Fascinating new prospects for biomarker develop-
ment come from recent advances in genetics.
Genome-wide association studies and pathway analyses
are powerful tools which have added new candidate
genes to the list of genetic risk factors for MS.
Although each individual gene makes only a minute
contribution to the overall genetic risk of MS, certain
combinations of factors may confer clinically relevant
risk.42
An intriguing recently discovered risk factor for MS
is the R92Q variant of the TNFRSF1A gene.
43,44 This
locus is of special interest because the R92Q substitu-
tion was previously detected in a special subgroup of
MS patients.45,46 MS patients with this mutation have
additional symptoms compatible with the autoinflam-
matory syndrome TRAPS (TNF receptor 1-associated
periodic syndrome). TRAPS is an autoinflammatory
disorder which typically manifests in childhood, and
is usually characterized by unprovoked episodes of sys-
temic inflammation with fever, abdominal pain, myal-
gia, cutaneous inflammation, arthralgia and ocular
involvement. Interestingly, most patients with MS and
TRAPS have a late-onset form of TRAPS with arthral-
gia, myalgia, skin involvement, severe fatigue and head-
ache, but without the otherwise typical fever
episodes.45,46
Initially, it was unclear whether the occurrence of
MS and TRAPS in individual patients represented a
pure coincidence, or whether the two distinct disorders
might have a pathogenetic relationship (Figure 20).
In some (but not all) families, TRAPS and MS seem
to be inherited together (Figure 21). De Jager et al.
subsequently demonstrated that indeed there is an
association between MS susceptibility and the R92Q
Figure 19. Tailored (personalized) therapy depends on the
availability of biomarkers to differentiate between different types
of disease.
Box 3A. Multiple sclerosis features for which biomarkers are
needed
 (Differential)
diagnosis of MS
 Demyelination
and remyelination
 Pathogenetic
heterogeneity
 Disease activity  Course of MS  Predisposition
 Prognosis  Therapeutic response  Axonal loss
Box 3B. Types of biomarkers
 Imaging techniques
(MRI, MRS, OCT, etc)
 Electrophysiological
testing
 Immunological assays  Genetic markers
 Others
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amino acid substitution.43,44 Taken together, these sep-
arate lines of evidence shed a new light on the relation-
ship between MS and the TNF pathways,
demonstrating that the results of large genome-wide
studies and clinical bedside observations may converge
to uncover fascinating clinical and pathophysiological
relationships. The TRAPS-related mutation R92Q may
be also be relevant for the therapy of MS: in
pilot studies we observed that patients with this muta-
tion are more prone to side effects of various
immunotherapies. Perhaps this and other related
mutations might eventually serve as therapeutic
biomarkers.
Conclusion
It is impossible for mere mortals to look into the future.
The challenges discussed here in the 2009 ECTRIMS
lecture may be outdated in 5 or 10 years from now.
Whatever the fate of the ‘five future challenges’,
ECTRIMS is likely to survive well into the future.
However, we should not be aiming primarily at break-
ing the 10,000 participants sonic barrier, but rather get
on with our research into the pathogenesis and treat-
ment of MS. For discussing progress and exchanging
ideas, ECTRIMS is and will remain an ideal forum.
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